帕金森病虚拟现实训练的剂量反应关系:对整体运动功能,功能移动性和平衡信心的元分析
Archives of physical medicine and rehabilitation
|March 12, 2026
概括
虚拟现实培训 (VRT) 在帕金森病 (PD) 中显著改善功能移动性 (TUG) 和平衡信心 (ABC). 高频率VRT (≥4次/周) 可能有利于运动功能 (UPDRS-III).
科学领域:
- 神经科学是一个神经科学.
- 康复医学 康复医学 康复医学
- 数字健康数字健康
背景情况:
- 帕金森病 (PD) 显著影响运动功能,移动性和平衡.
- 优化康复方案对于管理PD症状和改善生活质量至关重要.
- 虚拟现实培训 (VRT) 为PD康复提供了一个有希望的,以技术为导向的方法.
研究的目的:
- 确定VRT对PD患者运动功能 (UPDRS-III),功能移动性 (TUG) 和平衡信心 (ABC) 的剂量反应关系.
- 确定最佳的VRT参数,以最大限度地提高PD的康复效益.
- 评估VRT在PD管理中的临床实用性和潜力.
主要方法:
- 在六个主要数据库中进行了系统的文献搜索,确定了31项随机对照试验 (RCT),涉及1110名PD患者.
- 数据提取集中在文献详细信息,参与者特征,干预特点和TUG,UPDRS-III和ABC分数的定量结果上.
- 根据PRISMA指南进行了元回归分析,以分析剂量反应关系并确定最佳训练参数.
主要成果:
- VRT显著改善了TUG (WMD = -3.69) 和ABC (WMD = 11.80),两者都超过了最小临床重要差异 (MCID).
- 优化TUG改善的最佳VRT参数包括21-40分钟/会议,每周4-7次,为6-8周.
- 高频训练 (≥4次/周) 是必要的,以显著改善UPDRS-III,尽管对UPDRS-III的整体影响是有限的.
结论:
- 虚拟视觉疗法,特别是与物理治疗相结合时,显著提高了PD患者的功能移动性 (TUG) 和平衡信心 (ABC),达到临床意义 (MCID).
- 虽然VRT单独显示了TUG的改善,但它没有达到MCID. 高频协议显示了改善运动功能的潜力 (UPDRS-III).
- 每周4-7次的训练频率与TUG的临床重要改善有关,这表明剂量依赖的效果.
相关概念视频
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:15Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
01:22Dose-Response Relationship: Potency and Efficacy
7.1K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
7.1K
01:03Dose-Response Relationship: Overview
5.6K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
5.6K